Comparative analysis of BRAF, NRAS and c‐KIT mutation status between tumor tissues and autologous tumor cell‐lines of stage III/IV melanoma. Issue 1 (8th December 2014)

• Record Type: Journal Article
• Authors: Knol, Anne‐Chantal; Pandolfino, Marie‐Christine; Vallée, Audrey; Nguyen, Frédérique; Lella, Virginie; Khammari, Amir; Denis, Marc; Puaux, Anne‐Laure; Dréno, Brigitte
• Is Part Of: Experimental dermatology. Volume 24:Issue 1(2015:Jan.)
• Page Start: 70
• Page End: 73
• Publication Date: 2014-12-08
• Subjects: Dermatology -- Periodicals; 616.5
• DOI: 10.1111/exd.12584
• Languages: English
• ISSNs: 0906-6705

Abstract

<abstract abstract-type="main" id="exd12584-abs-0001"> <title>Abstract</title> <p>In the last decade, advances in molecular biology have provided evidence of the genotypic heterogeneity of melanoma. We analysed <italic>BRAF</italic>, <italic> NRAS</italic> and <italic>c‐KIT</italic> alterations in tissue samples from 63 stage III/IV melanoma patients and autologous cell‐lines, using either allele‐specific or quantitative PCR. The expression of <italic>BRAF</italic> V600E protein was also investigated using an anti‐BRAF antibody in the same tissue samples. 81% of FFPE samples and tumor cell‐lines harboured a genetic alteration in either <italic>BRAF</italic> (54%) or <italic>NRAS</italic> (27%) oncogenes. There was a strong concordance (100%) between tissue samples and tumor cell‐lines. The <italic>BRAF</italic> V600E mutant‐specific antibody showed high sensitivity (96%) and specificity (100%) for detecting the presence of a <italic>BRAF</italic> V600E mutation. The correlation was of 98% between PCR and immunohistochemistry results for <italic>BRAF</italic> mutation. These results suggest that <italic>BRAF</italic> and <italic>NRAS</italic> mutation status of tumor cells is not affected by culture conditions.</p> </abstract>